EXACT Therapeutics AS: Share capital increase registered
Oslo, 26 March 2026: Reference is made to the stock exchange announcements by EXACT Therapeutics AS ("EXACT-Tx" or the "Company") published on 27 February 2026 and 13 March 2026 regarding exercise of warrants and the extraordinary general meeting to issue the new shares pursuant to the warrants exercise.
The issuance of the shares has now been registered with the Norwegian Register of Business Enterprises (Nw: Foretaksregisteret). Following registration of the share capital increase, the Company’s share capital is NOK 446,176.244, divided into 111,544,061 shares, each with a nominal value of NOK 0.004.
This information is subject to the disclosure requirements in section 5-12 of the Norwegian Securities Trading Act.
For more information, please contact: Per Walday, CEO Email per.walday@exact-tx.com John M. Edminson, CFO Email: john.edminson@exact-tx.com
About EXACT Therapeutics: EXACT Therapeutics is a clinical-stage precision medicine company utilizing the power of ultrasound to activate the proprietary drug PS101 and enhance the clinical benefit of oncology therapies. PS101 has a unique mode of action and may be combined with a wide range of therapeutic agents within oncology and across a multitude of other indications, including brain diseases. EXACT Therapeutics’ shares are traded on Euronext Growth Oslo (EXTX). Further information may be found here: www.exact-tx.com